Anteris Technologies initiated with an Overweight at Barclays

Barclays analyst Matt Miksic initiated coverage of Anteris Technologies (AVR) with an Overweight rating and $22 price target The timing for the company’s entry into transcatheter aortic valve replacement “could not look better,” the analyst tells investors in a research note. The firm says the market is now “deeply entrenched” between the preference for balloon-expandable valve and the need for hemodynamics in smaller valves. It believes Anteris ‘ DurAVR can provide balloon-expandable valve delivery for all valve sizes, and meet the growing demand for valve replacement.